Respiratory syncytial virus infection in adults aged 45 years or older is significantly associated with a higher 1-year risk ...

Nirsevimab is recommended for preventing RSV lower respiratory tract infection in infants younger than one year in their ...

Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...

Respiratory syncytial virus, commonly known as RSV, is often associated with cold-like symptoms in young children.

It may feel like you are surrounded by sniffles and coughs, but flu season activity is still low in many parts of the U.S.

The American Academy of Pediatrics has issued updated recommendations for RSV prevention in infants and high-risk young children.

A new study has found that a significant percentage of adults in the United States have at least one risk factor for severe respiratory syncytial virus (RSV), even as eligibility for the RSV ...

GSK (GSK) stock is in focus as an expert panel of the European Medicines Agency ((EMA)) endorses the company's Arexvy RSV ...

COVID-19, RSV, and influenza immunizations show continued safety and substantial effectiveness against hospitalization across various populations.

EMA committee recommends approval of GSK’s RSV vaccine, Arexvy for all adults 18 years and older: London, UK Saturday, December 13, 2025, 13:00 Hrs [IST] GSK plc announced that ...

Early-life viral infection programs immune cells to hijack allergy-associated maternal antibodies, driving allergy risk later ...